Simultaneous detection of thousands of actionable somatic mutations across 161 genes relevant to oncogenesis

Targeted therapy
Prognosis of disease
Relevant, on-going clinical trial information

Results in Less Than 48 Hours!

Bladder cancer
Breast cancer
Colorectal cancer
Endometrial cancer
Esophageal cancer
Gastric cancer
GIST
Glioblastoma
Head and neck cancer kidney cancer
Liver cancer
Lung cancer
Melanoma
Mesotelioma
NSCLC
Osteosarcoma
Ovarian cancer
Pancreatic cancer
Prostate cancer
Skin basal cell carcinoma
SLCLC
Soft tissue sarcome
Testicular cancer
Thyroid cancer
Unspecified cancer
Unspecified solid tumor

AKT1, AKT2, AKT3, ALK, AR, ARAF, AXL, BRAF, BTK, CBL, CCND1, CDK4, CDK6, CHEK2, CSF1R, CTNNB1, DDR2, EGFR, ERBB2, ERBB3, ERBB4, ERCC2, ESR1, EZH2, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, FOXL2, GATA2, GNA11, GNAQ, GNAS, H3F3A, HIST1H3B, HNF1A, HRAS, IDH1, IDH2, JAK1, JAK2, JAK3, KDR, KIT, KNSTRN, KRAS, MAGOH, MAP2K1, MAP2K2, MAP2K4, MAPK1, MAX, MDM4, MED12, MET, MTOR, MYC, MYCN, MYD88, NFE2L2, NRAS, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPP2R1A, PTPN11, RAC1, RAF1, RET, RHEB, RHOA, ROS1, SF3B1, SMAD4, SMO, SPOP, SRC, STAT3, TERT, TOP1, U2AF1, XPO1

ARID1A, ATM, ATR, ATRX, BAP1, BRCA1, BRCA2, CDK12, CDKN1B, CDKN2A, CDKN2B, CHEK1, CREBBP, FANCA, FANCD2, FANCI, FBXW7, MLH1, MRE11A, MSH2, MSH6, NBN, NF1, NF2, NOTCH1, NOTCH2, NOTCH3, PALB2, PIK3R1, PMS2, POLE, PTCH1, PTEN, RAD50, RAD51, RAD51B, RAD51C, RAD51D, RB1, RNF43, SETD2, SLX4, SMARCA4, SMARCB1, STK11, TP53, TSC1, TSC2

AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT
AKT1, AKT2, AKT3, ALK, AR, AXL, BRAF, CCND1, CCND2, CCND3, CCNE1, CDK2, CDK4, CDK6, EGFR, ERBB2, ESR1, FGF19, FGF3, FGFR1, FGFR2, FGFR3, FGFR4, FLT3, IGF1R, KIT, KRAS, MDM2, MDM4, MET, MYC, MYCL, MYCN, NTRK1, NTRK2, NTRK3, PDGFRA, PDGFRB, PIK3CA, PIK3CB, PPARG, RICTOR, TERT

A solid tumor is an abnormal mass of tissue that is free from cysts or liquid. There are three classes of malignant solid tumors: sarcomas, carcinomas and lymphomas. Old school treatments depend only on the cancer’s location, the stage, and the patient’s health. New targeted therapies are specific for the individual patient’s mutational profile, which requires advanced sequencing technology. Ayass BioScience, LLC has the capability to provide this much needed information for precision therapies.

Our test will help with:

1. Targeted therapies
2. Prognostic Information
3. Distinguishing between Primary vs Metastatic Cancers
4. Identification of relevant, on-going clinical trials

We strongly recommend that you seek genetic counseling to understand the limitations and possible consequences of this test.

All tests are performed in Ayass BioScience, LLC. Ayass BioScience, LLC (DBA Ayass Laboratory, LLC) is a CLIA certified laboratory. If you have any questions about COVID-19 Testing, Genetic Testing, Clinical Testing, Pharmacogenetic Testing or Research at Ayass BioScience, LLC, please call today at 972-668-6005 or fill out our contact form on the bottom of this page. We will answer any question you might have.